Genome mining in Streptomyces violaceusniger a prolific antibiotic producer
Complex polyketides are microbial natural products (including clinically-useful medicines) whose chemical structures correlate with the sequence of the modular enzymes responsible for their biosynthesis. This unique paradigm means...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EXPLOGEN
Exploitation of actinomycetes genomics using synthetic and s...
1M€
Cerrado
BIO2017-82462-R
IDENTIFICACION Y CARACTERIZACION DE AGRUPAMIENTOS DE GENES B...
218K€
Cerrado
COMMUNITY
Unraveling the regulatory networks in Streptomyces that swit...
3M€
Cerrado
RTI2018-093562-B-I00
CARACTERIZACION DE RUTAS DE COMPUESTOS BIOACTIVOS EN ACTINOM...
339K€
Cerrado
BIO2012-34723
EXPRESION DIFERENCIAL DE AGRUPACIONES PARA LA BIOSINTESIS DE...
105K€
Cerrado
BIO2014-56752-R
ACTIVACION Y CARACTERIZACION DE RUTAS DE BIOSINTESIS DE COMP...
218K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Complex polyketides are microbial natural products (including clinically-useful medicines) whose chemical structures correlate with the sequence of the modular enzymes responsible for their biosynthesis. This unique paradigm means that the structure of the gene can be inferred from the chemical structure of the molecule, and (with less certainty) the reverse is true. Now, genome-scale sequencing of actinomycetes has revealed untapped chemical diversity in culturable streptomycetes: there are many biosynthetic clusters present but most are cryptic (silent). Expression of biosynthetic genes is now a severe bottleneck in trying to develop a genuine synthetic biology of natural products, in which PKSs are designed and fabricated to order to produce a specificed target molecule. We have sequenced and will study an extreme example of one strain-many clusters: a strain of Streptomyces violaceusniger which houses 11 clusters (of which seven silent and some are novel). We will: (1) use in-frame PKS gene deletion followed by chemical analysis of the resulting mutants, to test whether and how inactivation of one pathway affects the simultaneous production of others; (2) attempt to activate cryptic pathway genes by alterations in regulatory genes and by ribosome engineering, and isolate any new products; (3) clone whole PKS clusters in high-yielding (and sequenced) strains of, respectively, the monensin-producing Streptomyces cinnamonensis and the erythromycin-producing Saccharopolyspora erythraea for heterologous expression of polyketides in pre-optimised backgrounds; and (4) use genome reduction triggered by cre-loxP recombination, to radically simplify the secondary metabolite profile of all three strains and test the mutants for improved expression of cloned PKS genes.